pharmaphorum October 23, 2024
Phil Taylor

US Senators are concerned that Pfizer and Eli Lilly’s recent forays into direct-to-consumer distribution of medicines via telehealth platforms could violate federal anti-kickback laws.

The four Senators – Democrats Dick Durbin, Peter Welch, Elizabeth Warren, and independent Bernie Sanders – have sent letters to the CEOs of the two pharma groups expressing the concern that their new arrangements “steer patients toward particular medications and create the potential for inappropriate prescribing that can increase spending for federal health care programmes.”

Lilly made the first move in this direction with the launch of its LillyDirect service in January, offering access to several of its medicines – including weight-loss therapy Zepbound (tirzepatide) – claiming the move would streamline the supply chain and reduce...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Digital Health, Govt Agencies, Pharma, Pharma / Biotech, Technology, Telehealth
PBM reform dropped in Congress' funding package
2025 and Beyond: Key Trends to Watch in Pharmacy
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
What's next for Amazon in healthcare?

Share This Article